Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

A Safety and Immunogenicity Evaluation of a Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) and a Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in Subjects 56 Years of Age or Older

Safety:

To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination with either Menactra® vaccine or Menomune® vaccine.

Immunogenicity:

To evaluate the immune response to serogroups A, C, Y, and W-135 in each of the four study groups.

Study Overview

• Status: Completed
• Conditions: Meningococcal Infections; Meningococcal Meningitis
• Intervention / Treatment: Biological: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide; Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate

• Study Type: Interventional
• Enrollment (Actual): 216
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85251
  • Kentucky
    • Bardstown, Kentucky, United States, 40004
  • New Mexico
    • Albuquerque, New Mexico, United States, 87108
  • Utah
    • West Jordon, Utah, United States, 84088
  • Washington
    • Seattle, Washington, United States, 98101
    • Spokane, Washington, United States, 99202

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 56 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Ambulatory and healthy, as determined by medical history.
• 56 years of age or older at the time of vaccination.
• Signed Institutional Review Board (IRB)-approved informed consent form.
• Able to attend all scheduled visits and to comply with all trial procedures.
• For a woman, inability to become pregnant or a negative urine pregnancy test at the time of enrollment.

Exclusion Criteria:

• Any condition which, in the opinion of the Investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
• Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc) that is unstable or that might 1) interfere with the ability to participate fully in the study or 2) interfere with evaluation of the vaccines.
• Known or suspected impairment of immunologic function.
• Febrile illness within the last 72 hours or an oral temperature ≥ 100.4ºF at the time of inclusion.
• History of documented invasive meningococcal disease or previous meningococcal vaccination.
• Known or suspected receipt of a diphtheria-containing vaccine within the preceding 2 years.
• Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
• Systemic antibiotic therapy within the 72 hours prior to collection of any blood samples.
• Received any vaccine in the 28-day period prior to enrollment or scheduled to receive any vaccination through Visit 2 for Groups 1 and 2 and through Visit 3 for Groups 3 and 4. Influenza vaccines may be received 2 weeks before or after a study vaccination.
• Suspected or known hypersensitivity to latex or to any of the components of either Menactra® vaccine or Menomune® vaccine.
• Previous personal history of Guillain-Barré syndrome.
• Not available for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
• In females of childbearing potential, a positive or equivocal urine pregnancy test at enrollment.
• A nursing mother.
• Participation in another interventional clinical trial in the 4 weeks preceding enrollment or planning to participate in another interventional clinical trial during the planned period of this study.
• Current use of alcohol or recreational drugs that may interfere with the subject's ability to comply with trial visits or procedures.
• Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.
• Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Group 1: Menomune Day 0; Participants received a single dose of Menomune® vaccine on Day 0.	Biological: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide; 0.5 mL, Subcutaneous; Other Names: Menomune®
Experimental: Group 2: Menactra® Day 0 x 2; Participants received two single-dose injections of Menactra® vaccine on Day 0	Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL, Intramuscular; Other Names: Menactra®; Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL. Intramuscular; Other Names: Menactra®
Experimental: Group 3: Menactra® Day 0 and 14; Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14	Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL, Intramuscular; Other Names: Menactra®; Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL. Intramuscular; Other Names: Menactra®
Experimental: Group 4: Menactra® Day 0 and 28; Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.	Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL, Intramuscular; Other Names: Menactra®; Biological: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; 0.5 mL. Intramuscular; Other Names: Menactra®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With At Least One Solicited Injection Site or Systemic Reaction Post-Vaccination 1.	Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.	0-7 days post-vaccination 1
Number of Participants With At Least One Solicited Injection Site Reaction Post-Vaccination 2	Solicited injection site reactions: Pain, Erythema, and Swelling.	0-7 Days Post-vaccination 2
Number of Participants With At Least One Solicited Systemic Reaction Post-Vaccination 2	Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.	Day 0 to 7 Post-vaccination 2

Other Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Antibody Titers Using Baby Rabbit Complement (SBA-BR) Post-Vaccination 1.	Day 28 Post-vaccination 1
Percentage of Participants With at Least a 4-fold Rise in Serum Bactericidal Antibody Titers Using Baby Rabbit Complement (SBA-BR) Post-Vaccination 2	Day 28 Post-vaccination 2
Geometric Mean Titers (GMTs) of Serum Bactericidal Antibody Using Baby Rabbit Complement (SBA-BR) Pre- and Post-vaccination 1	Day 0 and Day 28 Post-vaccination 1
Geometric Mean Titers (GMTs) of Serum Bactericidal Antibody Using Baby Rabbit Complement (SBA-BR) Pre-vaccination 1 and Post-vaccination 2	Day 0 and 28 days Post-vaccination 2
Percentage of Participants Achieving Serum Bactericidal Antibody Using Baby Rabbit Complement (SBA-BR) Titers of at Least 1:8 (≥1:8) Pre- and Post-vaccination 1	Day 28 Post-vaccination 1
Percentage of Participants Achieving Serum Bactericidal Antibody Using Baby Rabbit Complement (SBA-BR) Titers of at Least 1:8 (≥1:8), Pre-vaccination 1 and Post-vaccination 2	Day 0 and Day 28 Post-vaccination 2

Collaborators and Investigators

• Sponsor: Sanofi Pasteur, a Sanofi Company

Publications and helpful links

Helpful Links

• Related Info
• Related Info

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): January 1, 2008
• Study Completion (Actual): October 1, 2008

Study Registration Dates

• First Submitted: March 31, 2009
• First Submitted That Met QC Criteria: March 31, 2009
• First Posted (Estimate): April 2, 2009

Study Record Updates

• Last Update Posted (Estimate): September 20, 2013
• Last Update Submitted That Met QC Criteria: September 12, 2013
• Last Verified: September 1, 2013

More Information

Terms related to this study

• Keywords: Menactra®; Meningococcal Vaccine; Menomune®
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Infections; Central Nervous System Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Neisseriaceae Infections; Meningitis, Meningococcal; Meningitis; Meningococcal Infections
• Other Study ID Numbers: MTA29